

10523843

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s threo DOPS

39976 THREO

8 DOPS

L1 2 THREO DOPS

(THREO(W)DOPS)

=> d 11

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN

RN 23651-95-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Tyrosine, β ,3-dihydroxy-, (β R)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Tyrosine, β ,3-dihydroxy-, threo-

CN Serine, 3-(3,4-dihydroxyphenyl)-, L-threo- (8CI)

OTHER NAMES:

CN (-)-threo-3,4-Dihydroxyphenylserine

CN DOPS

CN Droxidopa

CN L-DOPS

CN L-threo- β -(3,4-Dihydroxyphenyl)serine

CN L-threo-3,4-Dihydroxyphenylserine

CN L-threo-3-(3,4-Dihydroxyphenyl)serine

CN L-threo-DOPS

CN L-Threodops

CN SM 5688

CN threo-Dopaserine

FS STEREOSEARCH

MF C9 H11 N O5


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

218 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

219 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d 11 2-2

Jagoe

10523843

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 3916-18-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN D-Tyrosine, β ,3-dihydroxy-, (β S)-rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN DL-Tyrosine, β ,3-dihydroxy-, threo-
CN Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo- (8CI)
OTHER NAMES:
CN DL-threo-3,4-Dihydroxyphenylserine
CN DL-threo-Dihydroxyphenylserine
CN DL-threo-DOPS
CN threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid
FS STEREOSEARCH
DR 6204-89-3, 43160-12-9
MF C9 H11 N O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS,
CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA,
RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

110 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
110 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file MEDICINE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.76

14.97

FILE 'ADISCTI' ENTERED AT 12:26:39 ON 01 OCT 2008

COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:26:39 ON 01 OCT 2008

COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:26:39 ON 01 OCT 2008

COPYRIGHT (C) 2008 Adis Data Information BV

Jagoe

10523843

FILE 'BIOSIS' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:26:39 ON 01 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DISSABS' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DRUGMONOG2' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBAL' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'KOSMET' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

10523843

FILE 'MEDLINE' ENTERED AT 12:26:39 ON 01 OCT 2008

FILE 'NAPRALERT' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright 2008 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 12:26:39 ON 01 OCT 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 WIPO

FILE 'PHARMAML' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright 2008 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Informa UK Ltd.

FILE 'PHIN' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 Informa UK Ltd.

FILE 'SCISEARCH' ENTERED AT 12:26:39 ON 01 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USGENE' ENTERED AT 12:26:39 ON 01 OCT 2008
COPYRIGHT (C) 2008 SEQUENCEBASE CORP

FILE 'USPATFULL' ENTERED AT 12:26:39 ON 01 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 12:26:39 ON 01 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:26:39 ON 01 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 or threo DOPS or droxidopa
L2 1889 L1 OR THREO DOPS OR DROXIDOPA

=> s headache or migraine or tension or premenstrual or PMS
L3 2370013 HEADACHE OR MIGRAINE OR TENSION OR PREMENSTRUAL OR PMS

=> s l2 and l3
L4 111 L2 AND L3

=> s premenstrual headache
L5 21 PREMENSTRUAL HEADACHE

10523843

=> s tension headache
L6 9857 TENSION HEADACHE

=> s migraine
L7 184142 MIGRAINE

=> s headache
L8 368794 HEADACHE

=> s 15 or 16 or 17 or 18
L9 472840 L5 OR L6 OR L7 OR L8

=> s 14 and
MISSING TERM AFTER L4 AND
Operators must be followed by a search term, L-number, or query name.

=> s 14 and 19
L10 86 L4 AND L9

=> s 110 and PD<2002
6 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
15 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
22 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
29 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
32 FILES SEARCHED...
L11 15 L10 AND PD<2002

=> dup rem
ENTER L# LIST OR (END):111
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L11
L12 12 DUP REM L11 (3 DUPLICATES REMOVED)

=> d 112 1-12 ibib, kwic

L12 ANSWER 1 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2001:205909 USPATFULL
TITLE: Polymorphic form of a tachykinin receptor antagonist
INVENTOR(S): Crocker, Louis, Belle Mead, NJ, United States
Mccauley, James, Belle Mead, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20010041702	A1	20011115	<--
	US 6432953	B2	20020813	
APPLICATION INFO.:	US 2001-850370	A1	20010507	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-458168, filed on 9 Dec 1999, GRANTED, Pat. No. US 6229010			

NUMBER	DATE
--------	------

 PRIORITY INFORMATION: US 1997-51600P 19970702 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: J. ERIC THIES, Patent Department, Merck & Co., Inc,
 P.O. Box 2000, Rahway, NJ, 07065-0907
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 2079
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,1-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic. . . .

SUMM . . . antagonist useful in the in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis.

SUMM [0007] Evidence has been reviewed for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory. . . .

DETD [0015] and is a tachykinin receptor antagonist useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

DETD . . . the novel polymorphic form of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine, is a tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. Accordingly, the present invention is further concerned with pharmaceutical formulations comprising this polymorphic form as an active. . . .

DETD . . . particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine, asthma, and emesis in a mammal in need of such treatment. This activity may be demonstrated by the following assay.

DETD . . . and peripheral damage, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example,. . . .

DETD . . . chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intracranial pressure, gastro-oesophageal reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation,. . . .

DETD . . . such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

DETD . . . emesis, including acute, delayed or anticipatory emesis, such

as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intracranial pressure. Most especially, the compound of the present invention is of use in the treatment of. . .

DETD . . . such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain. The present invention further provides the compound of the present invention for use in. . .

DETD [0068] It will be appreciated that for the treatment or prevention of migraine, the compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists, especially sumatriptan or rizatriptan. Likewise, for the treatment of behavioural hyperalgesia, the compound. . .

DETD . . . azamianserin, bazinaprime, fefuraline, bifemelane, binodoline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dasepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, setazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprime, . . .

L12 ANSWER 2 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2001:67821 USPATFULL
 TITLE: Polymorphic form of a tachykinin receptor antagonist
 INVENTOR(S): Crocker, Louis, Belle Mead, NJ, United States
 McCauley, James, Belle Mead, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6229010	B1	20010508	<--
APPLICATION INFO.:	US 1999-458168		19991209	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-212511, filed on 15 Dec 1998, now patented, Pat. No. US 6096742			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51600P	19970702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Reamer, James H.	
LEGAL REPRESENTATIVE:	Thies, J. Eric, Rose, David L.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	2023	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms

of thermodynamic. . .

SUMM . . . antagonist useful in the in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis.

SUMM Evidence has been reviewed for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory. . .

DETD and is a tachykinin receptor antagonist usefull in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

DETD . . . the novel polymorphic form of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine, is a tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. Accordingly, the present invention is further concerned with pharmaceutical formulations comprising this polymorphic form as an active. . .

DETD . . . particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine, asthma, and emesis in a mammal in need of such treatment. This activity may be demonstrated by the following assay.

DETD . . . and peripheral damage, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example,. . .

DETD . . . chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intercranial pressure, gastro-oesophageal reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation,. . .

DETD . . . such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

DETD . . . emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. Most especially, the compound of the present invention is of use in the treatment of. . .

DETD . . . such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain. The present invention further provides the compound of the present invention for use in. . .

DETD It will be appreciated that for the treatment or prevention of migraine, the compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists, especially sumatriptan or rizatriptan. Likewise, for the treatment of behavioural hyperalgesia, the compound. . .

DETD . . . azamianserin, bazinaprime, fefuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine,

cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dasepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, setazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, . . .

L12 ANSWER 3 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2000:98427 USPATFULL
 TITLE: Polymorphic form of a tachykinin receptor antagonist
 INVENTOR(S): Crocker, Louis, Belle Mead, NJ, United States
 McCauley, James, Belle Mead, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096742		20000801 <--
APPLICATION INFO.:	US 1998-212511		19981215 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-108567, filed on 1 Jul 1998, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Thies, J. Eric, Rose, David L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1,3		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	2018		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic. . .

SUMM . . . antagonist useful in the in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis.

SUMM Evidence has been reviewed for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory. . .

DETD . . . 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine has the structure: ##STR1## and is a tachykinin receptor antagonist useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.

DETD . . . the novel polymorphic form of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine, is a tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. Accordingly, the present invention is further concerned with pharmaceutical formulations comprising this polymorphic form as an active. . .

DETD . . . particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders,

inflammatory diseases, pain or migraine, asthma, and emesis in a mammal in need of such treatment. This activity may be demonstrated by the following assay.

- DETD . . . and peripheral damage, such as acute trauma, osteoarthritis, rheumatoid arthritis, musculo-skeletal pain, particularly after trauma, spinal pain, myofascial pain syndromes, headache, episiotomy pain, and burns; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, . . .
- DETD . . . chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, for example, motion sickness, vertigo, dizziness and Meniere's disease, surgery, migraine, variations in intracranial pressure, gastro-oesophageal reflux disease, acid indigestion, over indulgence in food or drink, acid stomach, waterbrash or regurgitation, . . .
- DETD . . . such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and pain or nociception attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.
- DETD . . . emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intracranial pressure. Most especially, the compound of the present invention is of use in the treatment of. . .
- DETD . . . such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain. The present invention further provides the compound of the present invention for use in. . .
- DETD It will be appreciated that for the treatment or prevention of migraine, the compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists, especially sumatriptan or rizatriptan. Likewise, for the treatment of behavioural hyperalgesia, the compound. . .
- DETD . . . azamianserin, bazinaprine, fefuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dasepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, setazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, . . .

L12 ANSWER 4 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:17360 USPATFULL
 TITLE: Compositions and methods for topical administration of pharmaceutically active agents
 INVENTOR(S): Kanios, David P., Miami, FL, United States
 Gentile, Joseph A., Plantation, FL, United States
 Mantelle, Juan A., Miami, FL, United States
 Sablotsky, Steven, Miami, FL, United States
 PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc., Miami, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

10523843

PATENT INFORMATION: US 5719197 19980217 <--
APPLICATION INFO.: US 1995-477361 19950607 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-112330, filed
on 27 Aug 1993, now patented, Pat. No. US 5446070 which
is a continuation-in-part of Ser. No. US 1991-813196,
filed on 23 Dec 1991, now patented, Pat. No. US 5234957
which is a continuation-in-part of Ser. No. US
1991-661827, filed on 27 Feb 1991, now abandoned, said
Ser. No. US 1995-477361, filed on 7 Jun 1995 which is a
continuation-in-part of Ser. No. US 1993-67001, filed
on 26 May 1993 which is a continuation of Ser. No. US
1991-671709, filed on 2 Apr 1991, now patented, Pat.
No. US 5300291 which is a continuation-in-part of Ser.
No. US 1989-295847, filed on 11 Jan 1989, now patented,
Pat. No. US 4994267 which is a continuation-in-part of
Ser. No. US 1988-164482, filed on 4 Mar 1988, now
patented, Pat. No. US 4814168
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1799
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD ANTIPARKINSONIAN such as Amantadine, Benserazide, Bietanautine,
Biperiden, Budipine, Carbidopa, Deprenyl, Dexetimide, Diethazine,
Droxidopa, Ethopropazine, Ethylbenzhydramine, Levodopa,
Piroheptine, Pridinol, Prodipine, Terguride, Tiapride, Tigloidine

CLM What is claimed is:
. . . or muscarinic cholinergic blocking drugs, mydriatics, psychic
energizers, humoral agents, antispasmodic drugs, antidepressants,
antidiabetics, anorexic drugs, anti-allergic drugs, decongestants,
antipyretics, anti-migraine drugs, antimalarial, antiulcer
drugs, peptides, and anti-estrogens.

L12 ANSWER 5 OF 12 USPATFULL on STN
ACCESSION NUMBER: 97:27205 USPATFULL
TITLE: Threo-3-(3,4-dihydroxyphenyl)serine analgesic
composition
INVENTOR(S): Takagi, Hiroshi, Kyoto, Japan
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5616618		19970401	<--
	WO 9416689		19940804	<--
APPLICATION INFO.:	US 1995-495480		19950724	(8)
	WO 1994-JP120		19940128	
			19950724	PCT 371 date
			19950724	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-34366	19930129
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

Jagoe

PRIMARY EXAMINER: Cook, Rebecca
 LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
 NUMBER OF CLAIMS: 4
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 475
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . and chronic or continuous pains. Therefore, threo-3-(3,4-dihydroxyphenyl)serine is effective for the treatment of diseases with pains such as postoperative pain, headache, migraine, pains accompanied by rheumatism, post-herpes neuralgia, cancerous pain, pains associated with cervico-omo-brachial syndrome, shoulder periarthrititis, spinal distortion, and spondylosis deformans.

SUMM The present invention relates to a medical use of threo-3-(3,4-dihydroxyphenyl)serine (hereinafter abbreviated as threo-DOPS). More particularly, the present invention relates to a medical use of threo-DOPS as an analgesic drug, especially in the treatment of acute and chronic pains or continuous pains.

SUMM . . . made extensive studies to achieve the foregoing object. As a result, it has been discovered that a pharmaceutical composition comprising threo-DOPS as an effective ingredient exhibits an analgesic activity to relieve chronic or continuous pain as well as acute pain. The. . .

SUMM That is, the present invention relates to an analgesic composition comprising as an effective ingredient threo-DOPS or a pharmaceutically acceptable acid addition salt thereof.

SUMM . . . relates to a method for the treatment of diseases with pains which comprises administering to human an effective dose of threo-DOPS or a pharmaceutically acceptable acid addition salt thereof.

SUMM The present invention further relates to use of threo-DOPS or a pharmaceutically acceptable acid addition salt thereof in the production of an analgesic composition.

DRWD FIG. 1 shows the results of the analgesic effect of L-threo-DOPS assessed by the tail flick method.

DRWD FIG. 2 shows the results of the analgesic effect of L-threo-DOPS assessed by the kaolin-induced writhing test.

DRWD FIG. 3 shows the results of the analgesic effect of L-threo-DOPS assessed by the formalin-induced encroachment test.

DRWD FIG. 4 shows the results of morphine antagonist, naloxone, on the analgesic effect of L-threo-DOPS assessed by the tail flick method and the kaolin-induced writhing test.

DRWD FIG. 5 shows the results of adrenaline blocking agent, phentolamine, on the analgesic effect of L-threo-DOPS assessed by the tail flick method.

DRWD FIG. 6 shows the results of decarboxylase inhibitor, benserazide, on the analgesic effect of L-threo-DOPS assessed by the tail flick method.

DRWD FIG. 7 shows the results of the analgesic effect of L-threo-DOPS by oral administration, which was assessed by the tail flick method.

DETD Threo-DOPS used in the present invention is a known compound represented by the following formula: ##STR1## This compound may be prepared according to known methods as reported in Japanese Patent Application KOKOKU No. 1-49139 and U.S. Pat. No. 4,480,109. Threo-DOPS has optically active L- and D-forms and racemic DL-form. Among them, L-threo-DOPS is

preferred for the purpose of the present invention. Since 1989, L-Threo-DOPS has been clinically applied to improve freezing gait observed in Parkinson's disease.

- DETD In the present invention, threo-DOPS may be employed also in the form of pharmaceutically acceptable acid addition salts thereof. To form the acid addition salts, . . .
- DETD According to the present invention, threo-DOPS or its pharmaceutically acceptable acid addition salts may also be used in combination with a decarboxylase inhibitor. Preferred examples of. . .
- DETD It is known that, after administration, threo-DOPS is transported to a brain that is a site on which threo-DOPS acts, and then decarboxylated therein into a corresponding noradrenaline by decarboxylase to exhibit an activity for the treatment of Parkinson's disease (U.S. Pat. No. 4,497,826). It is also known that, where threo-DOPS is administered in combination with the decarboxylase inhibitor, decarboxylation of threo-DOPS by decarboxylase in the peripheral tissue can be prevented, resulting in that the transportation of threo-DOPS into a brain can be accelerated. As a result, a dose of threo-DOPS to be administered as a drug for treating Parkinson's disease may be reduced, and side effects of threo-DOPS in the peripheral tissue may be reduced (J. Pharm. Pharmacol., 1981, 33, 772-777).
- DETD As will be noted from test examples described hereinafter, threo-DOPS in the present invention is also considered to be transported into a brain and converted therein into noradrenaline to exhibit an analgesic effect. It is thus expected in the present invention that the combination of threo-DOPS with decarboxylase inhibitors will reduce a dose of threo-DOPS as an analgesic, and will therefore prevent side effects in the peripheral tissue.
- DETD Threo-DOPS or its pharmaceutically acceptable acid addition salt which is an effective ingredient of the present invention may be administered orally. . . dose in a conventional dosage form. Examples of preparations for oral administration include a tablet, capsule, syrup and suspension. Alternatively, threo-DOPS may also be administered parenterally in the dosage form of injection as a solution, emulsion or suspension.
- DETD . . . by mixing the effective ingredient with a pharmaceutically acceptable and conventionally used carrier, excipient, binder, stabilizer and the like. Where threo-DOPS is administered in the dosage form of an injection, the composition may be formulated with a pharmaceutically acceptable buffer, solution aid, isotonic solution and the like. As pointed out hereinbefore, threo-DOPS has already been provided for clinical use, and those preparations may be, therefore, used as they are.
- DETD Where threo-DOPS is administered in combination with a decarboxylase inhibitor, a kit comprising threo-DOPS or its pharmaceutically acceptable acid addition salt and a decarboxylase inhibitor is prepared and the thus prepared kit may be. . .
- DETD A dose and dosage frequency of threo-DOPS or its pharmaceutically acceptable acid addition salt may vary depending upon the dosage form, conditions of disease to be treated, . . .
- DETD . . . combination with the effective ingredient, it is sufficient to administer the inhibitor in a dose less than the dose of threo-DOPS by about 1/10.
- DETD Threo-DOPS has an extremely weak toxicity, that is, LD₅₀ is 10 g/kg or more when orally administered to mouse, and about. . .

DETD The analgesic composition of the present invention is effective for treating pains such as postoperative pain, headache, migraine, pains accompanied by rheumatism, post-herpes neuralgia, cancerous pain, pains associated with cervico-omo-brachial syndrome, shoulder periarthrititis, spinal distortion, and spondylosis deformans.

DETD That is, it has been confirmed that the analgesic composition of the present invention comprising threo-DOPS as an effective ingredient has the effects set forth below, as will be noted from test examples hereinafter.

DETD . . . latency by administration of a drug (tail-flick test, see European Journal of Pharmacology, 212, 1992). The tail-flick test reveals that threo-DOPS exhibits the analgesic effect dose-dependently when subcutaneously administered to mice.

DETD . . . model for assessment of chronic pain is used [Pain, 51, 195-198 (1992)]. The analgesic effect was dose-dependently observed when threo-DOPS was administered subcutaneously and orally.

DETD (3) Mechanism of the Analgesic Effect of Threo-DOPS

DETD The analgesic effect of threo-DOPS is non-narcotic, because the effect was not antagonized by morphine antagonist, naloxone. Furthermore, the analgesic effect of threo-DOPS was suppressed by the administration of an adrenaline blocker, phentolamine, in the brain, and thus shown to act via adrenergic nerve in the brain. Such pharmacological properties of threo-DOPS are quite dissimilar to those of conventional analgesics.

DETD These results reveal that threo-DOPS or pharmaceutically acceptable acid addition salt thereof used in the present invention have a mechanism different from that of known. . .

DETD Antinociceptive tests for L-threo-DOPS

DETD L-Threo-DOPS was suspended in a 0.2% Tween 80 solution and the resulting suspension was subcutaneously administered in a dose of 100. . .

DETD . . . shown in FIG. 1. The left graph in FIG. 1 shows latency with passage of time after subcutaneous administration of L-threo-DOPS in a dose of 400 mg/kg according to the tail flick test. In the left graph, the symbol .largecircle. denotes the group administered with vehicle only (n=8), and the symbol .circle-solid. denotes the group administered with L-threo-DOPS (n=5). The right graph in FIG. 1 shows a relationship between the dose of L-threo-DOPS administered and latency (second) one hour after administration of L-threo-DOPS. In the right graph, the symbol V denotes the group administered with vehicle only. *P<0.05, **P<0.01 (when compared to the. . .

DETD As is seen from FIG. 1, 40 or more minutes after administration of L-threo-DOPS in a dose of 400 mg/kg, a significantly prolonged latency was observed, and reached the maximum latency one hour after. . . was gradually recovered, and no significant effect was observed 2 hours later (see the left graph). The antinociceptive action of L-threo-DOPS, 60 minutes after administration, was dose-dependent in the range of 100 to 400 mg/kg (see the right graph).

DETD Thirty minutes, 1 hour and 2 hours before administration of kaolin, L-threo-DOPS was subcutaneously administered in a dose ranging from 100 to 400 mg/kg.

DETD . . . FIG. 2. The left graph in FIG. 2 shows the total count of writhing reactions with passage of time, after L-threo-DOPS was subcutaneously administered in a dose of 200 mg/kg according to the kaolin-induced writhing method. In the left graph, the symbol .largecircle. denotes the group administered with vehicle only, and the symbol .circle-solid. denotes the group administered with L-

threo-DOPS. The right graph in FIG. 2 shows a relationship between the dose of L-threo-DOPS administered and the total count of writhing reactions one hour after administration of L-threo-DOPS. The symbol V denotes the group administered with vehicle only (n=5). **P<0.01, ***P<0.001 (when compared to the group administered with. . .

DETD As is seen from FIG. 2, after administration of L-threo-DOPS in a dose of 200 mg/kg, the count of kaolin-induced writhing response decreased to the half, indicating a significant antinociceptive action. The decreasing tendency was also observed 30 minutes and 2 hours after administration of L-threo-DOPS, but the observed decrease was insignificant (see the left graph). The effect which was observed 60 minutes after administration of L-threo-DOPS was dose-dependent in the range of 100 to 400 mg/kg (see the right graph).

DETD Fifty minutes before the formalin administration, L-threo-DOPS was subcutaneously administered in a dose ranging from 100 to 200 mg/kg.

DETD . . . times required for licking and biting (second) for Phase I (0-5 minutes after the formalin administration) and the dose of L-threo-DOPS administered. The right graph in FIG. 3 shows in the formalin-induced nociceptive test (n=9-11) a relationship between the times required for licking and biting (second) for Phase II (10-30 minutes after the formalin administration) and the dose of L-threo-DOPS administered. The symbol V denotes the group administered with vehicle only. *P<0.05 (as compared to the group administered with vehicle. . .

DETD As is seen from FIG. 3, subcutaneous administration of L-threo-DOPS in a dose of 100 to 200 mg/kg did not affect the time required for the nociceptive reaction for Phase. . . inhibited the reaction for Phase II (the right graph). While not shown in the graphs, even though the dose of L-threo-DOPS was increased to 400 mg/kg, no better effect was obtained.

DETD Antagonistic Effect of L-threo-DOPS Antinociceptive Action on Naloxone (Morphine Antagonist)

DETD . . . tail flick test method, however, 1 mg/kg of naloxone was subcutaneously administered 40 minutes after administration of 400 mg/kg of L-threo-DOPS, and the latency was measured 60 minutes after the 400 mg/kg L-threo-DOPS administration. The obtained data are shown in terms of change in latency (Δ latency). In the kaolin-induced writhing test, 0.01 mg/kg of naloxone was subcutaneously administered 55 minutes after administration of 400 mg/kg of L-threo-DOPS, and kaolin was administered 5 minutes after the administration of naloxone.

DETD . . . FIG. 4. The left graph in FIG. 4 shows change in latency (Δ latency (second)) 60 minutes after administration of L-threo-DOPS according to the tail flick method (n=1). The right graph in FIG. 4 shows the total count of writhing reactions 60 minutes after administration of L-threo-DOPS according to the kaolin-induced writhing test (n=4 or 5). The symbol V denotes the group administered with vehicle only, and. . .

DETD As is seen from FIG. 4, the antinociceptive action of L-threo-DOPS in the tail flick test and the kaolin-induced writhing test was hardly affected by morphine antagonist, naloxone (Nlx). This reveals that the action of L-threo-DOPS is non-narcotic analgesic activity.

DETD Effect of Phentolamine as an α -Adrenaline Receptor Blocker on the Antinociceptive Action of L-threo-DOPS

DETD Phentolamine was administered intracerebral-ventricularly (i.c.v.) or intrathecally (i.th.) in a dose of 0.1 to 1 μ g/mouse, 40 minutes after

L-threo-DOPS was administered in a dose of 400 mg/kg. Then, the effect of phentolamine against L-threo-DOPS-induced antinociceptive action was determined in the tail flick test.

DETD . . . shown in FIG. 5. The results in FIG. 5 indicates change in latency (Δ latency, second) 60 minutes after the L-threo-DOPS administration. The left graph in FIG. 5 shows the effect of phentolamine when intracerebralventricularly (i.c.v.) administered, and the right graph. . .

DETD . . . phentolamine itself did not affect the latency. However, phentolamine almost completely inhibited prolongation of the latency by subcutaneous administration of L-threo-DOPS in a dose of 400 mg/kg (see the left graph). This effect by phentolamine was also observed even at a . . . μ g/mouse. On the other hand, when phentolamine was intracerebralventricularly administered in a dose of 1 μ g/mouse, the antinociceptive action of L-threo-DOPS (400 mg/kg, s.c.) was partially but significantly inhibited (see the right graph).

DETD The results shown in Test Examples 1 through 3 reveal that L-threo-DOPS exhibits a non-opiate type antinociceptive action by systemic administration. It is also suggested that noradrenergic system in the brain and. . .

DETD Effect of Benserazide (Peripheral Nerve Decarboxylase Inhibitor) on the Antinociceptive Action of L-threo-DOPS

DETD Benserazide was administered subcutaneously in a dose of 1 mg/kg, 60 minutes before the subcutaneous administration of L-threo-DOPS (400 mg/kg). Alternatively, benserazide was administered intracerebralventricularly at a dose of 25 μ g/mouse, 30 minutes before L-threo-DOPS was subcutaneously administered in a dose of 400 mg/kg. The effect of benserazide on the L-threo-DOPS-induced antinociceptive action 60 minutes after the L-threo-DOPS administration was examined according to the tail flick test.

DETD . . . shown in FIG. 6. The results in FIG. 6 indicate change in latency (Δ latency, second) 60 minutes after the L-threo-DOPS administration. The left graph in FIG. 6 shows the effect of benserazide when subcutaneously administered, and the right graph in. . .

DETD . . . as a peripheral decarboxylase inhibitor was administered subcutaneously, BSZ did not give any significant effect on the antinociceptive action of L-threo-DOPS (see the left graph). However, when benserazide was administered intracerebralventricularly, the antinociceptive action of L-threo-DOPS was potently inhibited (see the right graph).

DETD The foregoing results suggest that L-threo-DOPS would be transported into the central nervous system (brain and spinal code) after systemic administration, and decarboxylated therein by decarboxylase. . .

DETD Antinociceptive Action of L-threo-DOPS by Oral Administration

DETD L-Threo-DOPS was orally administered to mice in doses of 200, 400 and 800 mg/kg, and was examined for the antinociceptive action. . .

DETD . . . in FIG. 7. The results in FIG. 7 indicate, in the tail flick test, a relationship between the dose of L-threo-DOPS when orally administered and change in latency (Δ latency, second) 60 minutes after the L-threo-DOPS administration (n=6). *P<0.05, **P<0.01 (as compared to the control group).

DETD As is seen from FIG. 7, L-threo-DOPS shows the

antinociceptive action dose-dependently when orally administered in the range of 200 to 800 mg/kg. In all cases, a. . . administration, and reached the maximum level 60 minutes after the administration. Then, the effect gradually decreased. The results establish that L-threo-DOPS is also effective when orally administered.

DETD Two hundreds parts by weight of L-threo-DOPS, 167 parts by weight of excipient and 3 parts by weight of lubricant are uniformly mixed with each other. The mixture is then filled up in empty capsules to prepare capsules containing 200 mg of L-threo-DOPS.

DETD Hundred parts by weight of L-threo-DOPS, 168 parts by weight of excipient and 2 parts by weight of lubricant are uniformly mixed with each other. The mixture is then filled up in empty capsules to prepare capsules containing 100 mg of L-threo-DOPS

DETD According to the present invention, it has been revealed that threo-DOPS exhibits an analgesic activity which is effective for acute pains and chronic or continuous pains. Therefore, threo-DOPS is extremely effective for the treatment of diseases with pains such as postoperative pain, headache, migraine, pains accompanied by rheumatism, post-herpes neuralgia, cancerous pain, pains associated with cervico-omo-brachial syndrome, shoulder periarthrititis, spinal distortion, and spondylosis deformans.

IT 3916-18-5
(analgesic activity of)

L12 ANSWER 6 OF 12 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1996318047 EMBASE

TITLE: The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.

AUTHOR: Tanaka, H. (correspondence); Yamaguchi, H.; Mino, M.

CORPORATE SOURCE: Department of Pediatrics, Osaka Medical College, 2-7 Daigakucho, Takatsuki-shi, Osaka 569, Japan.

SOURCE: Clinical Autonomic Research, (1996) Vol. 6, No. 4, pp. 189-193.

Refs: 16

ISSN: 0959-9851 CODEN: CAURE9

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
007 Pediatrics and Pediatric Surgery

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 6 Nov 1996

Last Updated on STN: 6 Nov 1996

SO Clinical Autonomic Research, (1996) Vol. 6, No. 4, pp. 189-193.
Refs: 16

ISSN: 0959-9851 CODEN: CAURE9

CT Medical Descriptors:

adolescent
arterial pressure
article
blood pressure
clinical article
clinical trial

10523843

diastolic blood pressure
female
 headache: CO, complication
heart rate
human
lassitude: CO, complication
male
oral drug administration
*orthostatic hypotension: DT, drug therapy
school child
standing
supine position
syncope: CO, complication
systolic blood pressure
vertigo: CO, complication
noradrenalin: . . .

RN (noradrenalin) 1407-84-7, 51-41-2; (threo 3,4 dihydroxyphenylserine)
23651-95-8

L12 ANSWER 7 OF 12 ADISCTI COPYRIGHT (C) 2008 Adis Data Information BV on STN

ACCESSION NUMBER: 1996:44047 ADISCTI

DOCUMENT NUMBER: 800436605

TITLE: Analgesic effect of L-threo-3,4-dihydroxyphenylserine
(L-DOPS) in patients with chronic pain.
ADIS TITLE: Droxidopa: therapeutic use
Pain

In patients with chronic pain

AUTHOR: Takagi H; Harima A

CORPORATE SOURCE: Institute of Chronic Pain Research, Kyoto, Japan

SOURCE: European Neuropsychopharmacology (Mar 1, 1996),
Vol. 6, pp. 43-47

DOCUMENT TYPE: Best Evidence

ADIS REC. CREATED: 17 Apr 1996

RE Pain Control

LANGUAGE: English

WORD COUNT: 369

OTHER SOURCE: ADISINSIGHT 2007000260

ENTRY DATE: Entered STN: 30 Jun 1998

Last Updated on STN: 30 Jun 1998

PD 19960301

TI Analgesic effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients
with chronic pain.

ADIS TITLE: Droxidopa: therapeutic use
Pain

In patients with chronic pain

TX. . . noradrenaline does not cross the blood-brain barrier and therefore
has no analgesic effects in mammals. However, a synthetic amino acid,
droxidopa [L-threo-3,4-dihydroxyphenylserine, L-DOPS; Sumitomo],
acts as a noradrenaline precursor and has been shown to produce
naloxone-resistant antinociception in the mouse. This study assessed the
analgesic effect of oral administration of droxidopa in patients
with chronic pain.

TX. . . (mean 74) years

Sex: 4 male & 14 female

Disease: Pain

Characteristics: patients had chronic pain for > 6 months. Symptoms

included: cluster headache (n = 1); central pain after brain
infarction (3); spondylosis deformans, low back pain (10); neck-shoulder
syndrome (1); postherpetic neuralgia. . .

TX Droxidopa

Drug/Treatment	Dose	Route	Frequency	Duration
<u>Droxidopa</u> weeks	100-300 mg/dose	PO	bid-tid	4-5

TX Results:

	Placebo (n = 9)	<u>Droxidopa</u> (n = 9)
Mean VAS score (cm)	9.2	4.1 sup(a)
No. of patients with reduced intensity of. . .		8 sup(a)

CT Drug Descriptors: Droxidopa, therapeutic use

CT Disease Descriptors: Pain, treatment

L12 ANSWER 8 OF 12 ADISCTI COPYRIGHT (C) 2008 Adis Data Information BV on STN

ACCESSION NUMBER: 1995:4378 ADISCTI

DOCUMENT NUMBER: 800347428

TITLE: Clinical evaluation of Ro19-6327 (lazabemide hydrochloride) in patients with Parkinson's disease treated L-DOPA: double-blind, placebo-controlled, parallel-group, multicenter comparative study.
 ADIS TITLE: Lazabemide + levodopa: therapeutic use
 Parkinson's disease

AUTHOR: Narabayashi H; Mizuno Y; Yanagisawa N; Ogawa N; Miyatake T; et al.

CORPORATE SOURCE: Juntendo University School of Medicine, Tokyo, Japan

SOURCE: Rinsho Iyaku (Jan 1, 1995), Vol. 11, No. 2, pp. 363-391
 ISSN: 0910-8211

DOCUMENT TYPE: Best Evidence

ADIS REC. CREATED: 3 Apr 1995

RE Parkinson's Disease and Movement Disorders

LANGUAGE: Japanese

WORD COUNT: 392

OTHER SOURCE: ADISINSIGHT 1998003552; ADISINSIGHT 2006000619

ENTRY DATE: Entered STN: 30 Jun 1998

Last Updated on STN: 30 Jun 1998

PD 19950101

TX. . . were experiencing motor fluctuations, decreased efficacy or adverse effects.

Concomitant medication: levodopa, anticholinergics (n = 163), amantadine (147), dopaminergic agents (166), droxidopa (65), antihistamines, antidepressants, psychotropics, cerebral metabolism or cerebral circulation improvers, hypotensive and gastro-intestinal medications

SIDE. . . +

	levodopa	levodopa
Total	17 (11.4%)	31 (20.9%)
Nausea	2	7
Dry mouth	1	7
Stomach discomfort	4	4
<u>Headache</u> /heavy headedness	4	2
Dyskinesia	2	0
Dizziness	2	1
Delirium	1	0
Anxiety	1	0

10523843

Tremor exacerbation 1 0
Drowsiness. . .

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:622022 CAPLUS
DOCUMENT NUMBER: 121:222022
ORIGINAL REFERENCE NO.: 121:40189a,40192a
TITLE: Analgesic medicinal composition
INVENTOR(S): Takagi, Hiroshi
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9416689	A1	19940804	WO 1994-JP120	19940128 <--
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 06227973	A	19940816	JP 1993-34366	19930129 <--
JP 3559572	B2	20040902		
CA 2154455	A1	19940804	CA 1994-2154455	19940128 <--
EP 681838	A1	19951115	EP 1994-905224	19940128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
US 5616618	A	19970401	US 1995-495480	19950724 <--
PRIORITY APPLN. INFO.:			JP 1993-34366	A 19930129
			WO 1994-JP120	W 19940128
PI WO 9416689 A1	19940804			
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9416689	A1	19940804	WO 1994-JP120	19940128 <--
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 06227973	A	19940816	JP 1993-34366	19930129 <--
JP 3559572	B2	20040902		
CA 2154455	A1	19940804	CA 1994-2154455	19940128 <--
EP 681838	A1	19951115	EP 1994-905224	19940128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
US 5616618	A	19970401	US 1995-495480	19950724 <--
AB . . .	chronic or continuous pain and hence is remarkably efficacious as a remedy for pains and diseases such as postoperative pain, headache, migraine, rheumatic pain, postherpetic neuralgia, cancerous pain, neck-shoulder-arm syndrome, frozen shoulder, spinal sprain and spondylosis deformans. Formulations are given.			
IT 3916-18-5	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(analgesic activity of)			

L12 ANSWER 10 OF 12 ADISCTI COPYRIGHT (C) 2008 Adis Data Information BV on STN

ACCESSION NUMBER: 1992:50553 ADISCTI
DOCUMENT NUMBER: 800147973
TITLE: Clinical evaluation of selegiline hydrochloride (L-deprenyl) for the therapeutic drug in Parkinson's disease. Double-blind, comparative study in patients

Jagoe

treated between L-dopa combination and L-dopa alone.
 ADIS TITLE: Levodopa +- selegiline: therapeutic use
 Parkinson's disease
 AUTHOR: Takahashi M; Yuasa R; Imai T; Tachibana H; Yorifuji S; et
 al.
 CORPORATE SOURCE: Kinki University School of Medicine, Osaka, Japan
 SOURCE: Rinsho Iyaku (Jan 1, 1992), Vol. 8, No. 6, pp.
 1411-1453
 ISSN: 0910-8211
 DOCUMENT TYPE: Best Evidence
 ADIS REC. CREATED: 30 Jul 1992
 RE: Parkinson's Disease and Movement Disorders
 LANGUAGE: Japanese
 WORD COUNT: 381
 OTHER SOURCE: ADISINSIGHT 2000000457; ADISINSIGHT 2002000575; ADISINSIGHT
 2006000619
 ENTRY DATE: Entered STN: 30 Jun 1998
 Last Updated on STN: 30 Jun 1998

PD 19920101

TX. . . 40-75 (mean 62.4) years
 Sex: 63 male & 49 female
 Disease: Parkinson's-disease
 Concomitant medication: bromocriptine (n = 73), amantadine (54),
 anticholinergic agents (68), droxidopa (18); 106/112 patients
 received concomitant medication

SIDE. . . (11.7)
 anorexia 5 (8.3)
 dry mouth 4 (6.7)
 dyskinesia 4 (6.7)
 orthostatic hypotension 4 (6.7)
 headache 3 (5.0)
 No. (%) of patients 13 (25.0) 22 (36.7)
 experiencing
 adverse effects
 No. of patients withdrawn as. . .

L12 ANSWER 11 OF 12 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on
 STN DUPLICATE 1

ACCESSION NUMBER: 1992:164690 BIOSIS
 DOCUMENT NUMBER: PREV199293087015; BA93:87015
 TITLE: A CASE OF SYNDROME OF INAPPROPRIATE SECRETION OF
 ANTIDIURETIC HORMONE ASSOCIATED WITH DIABETES MELLITUS.
 AUTHOR(S): SATO K [Reprint author]; KIMURA T; OTA K; SHOJI M; INOUE M;
 OHTA M; YAMAMOTO T; CHIBA T; SAEKI S; ET AL
 CORPORATE SOURCE: SECOND DEP INTERN MED, TOHOKU UNIV SCH MED, 1-1 SEIRYO-CHO,
 AOBA-KU, SENDAI 980, JPN
 SOURCE: Endocrinologia Japonica, (1991) Vol. 38, No. 3,
 pp. 331-338.
 CODEN: ECJPAE. ISSN: 0013-7219.
 DOCUMENT TYPE: Article
 FILE SEGMENT: BA
 LANGUAGE: ENGLISH
 ENTRY DATE: Entered STN: 31 Mar 1992
 Last Updated on STN: 10 May 1992
 SO Endocrinologia Japonica, (1991) Vol. 38, No. 3, pp. 331-338.
 CODEN: ECJPAE. ISSN: 0013-7219.
 AB A 46-year-old man, presenting with headache, nausea, and
 lassitude, was diagnosed as having diabetes mellitus and hyponatremia, and
 admitted to Tohoku University Hospital. Insulin treatment improved. . .
 to an upright posture, accompanied by a fall in blood pressure and a rise

in heart rate. After treatment with droxidopa "a sympathomimetic drug", ambulatory blood pressure gradually increased and hyponatremia disappeared. However, blood pressure and ADH responses to upright posture. . . the baroreceptor reflex stimulated by the postural hypotension, and also by the impaired osmoregulation associated with diabetic neuropathy, and that droxidopa improved cardiovascular function and increased ANP release with resultant urinary dilution and natriuresis in spite of slightly increased ADH release.

IT Miscellaneous Descriptors

HUMAN DROXIDOPA AUTONOMIC-DRUG METABOLIC-DRUG SYMPATHETIC
NERVOUS SYSTEM BARORECEPTOR REFLEX ORTHOSTATIC HYPOTENSION
OSMOREGULATION

RN 23651-95-8 (DROXIDOPA)

L12 ANSWER 12 OF 12 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1987194691 EMBASE

TITLE: A case with acute pandysautonomia with aseptic meningitis - pathophysiological and therapeutic study.

AUTHOR: Ushiyama, M.; Ikeda, S.-I.; Yazawa, M.; et. al.

CORPORATE SOURCE: Department of Neurology, Shinshu University School of Medicine, Matsumoto, Japan.

SOURCE: Clinical Neurology, (1987) Vol. 27, No. 8, pp. 1035-1042.

ISSN: 0009-918X CODEN: RISHDJ

COUNTRY: Japan

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index

008 Neurology and Neurosurgery

LANGUAGE: Japanese

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 11 Dec 1991

Last Updated on STN: 11 Dec 1991

SO Clinical Neurology, (1987) Vol. 27, No. 8, pp. 1035-1042.

ISSN: 0009-918X CODEN: RISHDJ

AB . . . meningitis, and discuss the pathophysiology and therapy with L-threo-3,4-dihydroxyphenylserine (L-DOPS). The patient was a previously healthy 31-year-old male. He developed headache, abdominal pain, lumbago, and syncope when standing on January 15, 1986. Two days later, high fever, diarrhea and impotence appeared.. . .

RN (threo 3,4 dihydroxyphenylserine) 23651-95-8